康柏西普和雷珠单抗治疗早产儿视网膜病变的疗效分析

doi:10.3760/cma.j.cn115909-20210208-00054

摘要
图/表
参考文献(21)
相关文章 (12)

全文: PDF 710KB HTML (1 KB)
输出: BibTeX | EndNote (RIS) 背景资料

文章导读

摘要

目的：比较康柏西普和雷珠单抗治疗阈值前期1型早产儿视网膜病变（ROP）的疗效。方法：回顾性病例对照研究。选择2017年1月至2019年6月在解放军总医院第七医学中心儿科医学部住院治疗的阈值前期1型ROP且行抗血管内皮生长因子治疗的患儿107例（208眼），其中行康柏西普治疗（IVC）45例（86眼）作为IVC组，雷珠单抗治疗（IVR）62例（122眼）作为IVR组。IVC组中I区病变16例（32眼），II区病变29例（54眼）；IVR组中I区病变23例（46眼），II区病变39例（76眼）。术后定期随诊观察眼内炎症反应、ROP病变消退情况、ROP病变复发再治疗率和复发再治疗间隔时间。组间数据比较采用t检验和卡方检验。结果：2组间性别、出生胎龄、出生体质量、治疗时矫正胎龄、病变分区、急进型ROP构成差异均无统计学意义。IVR组和IVC组的复发再治疗率分别为45%和35%，其中I区为61%、63%，II区为37%、19%，2组间II区病变复发再治疗率差异有统计学意义（χ2=5.214，P=0.024）。IVR组和IVC组II区复发再治疗时间分别为注药后（8.8±2.5）周和（11.2±3.1）周，差异无统计学意义。结论：玻璃体腔注射雷珠单抗和康柏西普治疗ROP均有效，治疗后复发与病变分区有关，且康柏西普治疗II区病变复发再治疗率低于雷珠单抗的治疗。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	王宗华
	李秋平
	杨秀梅
	等

关键词 ：早产儿视网膜病变, 康柏西普, 玻璃体腔注射

Abstract：

Objective:To analyze the treatment ef?cacy of an intravitreal injection of conbercept (IVC) or ranibizumab (IVR) for type 1 retinopathy of prematurity (ROP).Methods:In this retrospectively case-control study,clinical records of 45 preterm infants (86 eyes) treated by IVC and 62 preterm infants (122 eyes) treated by IVR were retrospectively analyzed from January 2017 to June 2019. The intraocular in?ammatoryreaction,ROP disease regression and recurrence were observed regularly after the operation. In the IVC group, therewere 16 cases (32 eyes) in zone I and 29 cases (54 eyes) in zone II; In the IVR group, there were 23 cases (46 eyes) in zone I and 39 cases (76 eyes) in zone II. At-test and Chi-square test were used for data analysis.Results:There were no signi?cant differences in gender, gestational age, birth weight, corrected gestational age, lesion zoning or aggressive posterior retinopathy of prematurity between the two groups.The recurrence of treatment rates for IVR and IVC were 45% and 35%, respectively, of which 61% and 63% were in zone I, and 37% and 19% in zone II. The time of recurrence of treatment after injection was 8.8±2.5 and 11.2±3.1 weeks in zone II, and the difference is insigni?cant. There were signi?cant differencesin the rate of recurrence between the two groups (χ2=5.214,P=0.024).Conclusions:Intravitreal injection of conbercept and ranibizumab is an effective choice for ROP. The recurrence after treatment is related to the lesion area, the rate of recurrence was lower after injection of comber cept in zone II, but long-term safety needs to be evaluated further.

Key words： retinopathy of prematurity conbercept intravitreal injection

收稿日期: 2021-02-08

PACS:

基金资助:解放军总医院第七医学中心创新培育基金（2016-PY-LC-008）

通讯作者: 王宗华（ORCID：000-0002-3769-6713），Email：zonghuaw2002@163.com

引用本文:

王宗华,李秋平,杨秀梅,等. 康柏西普和雷珠单抗治疗早产儿视网膜病变的疗效分析 [J]. 中华眼视光学与视觉科学杂志, 2021, 23(11): 858-863. Zonghua Wang, Qiuping Li, Xiumei Yang,et al. Comparison of the Treatment Outcomes for Retinopathy of Prematurity with an Intravitreal Injection of Conbercept or Ranibizumab. Chinese Journal of Optometry Ophthalmology and Visual science, 2021, 23(11): 858-863. DOI: 10.3760/cma.j.cn115909-20210208-00054

链接本文:

https://www.cjoovs.com/CN/ 10.3760/cma.j.cn115909-20210208-00054 或 https://www.cjoovs.com/CN/Y2021/V23/I11/858

[1]	Early Treatment for Retinopathy of Prematurity Cooperative Group. Revised indications for the treatment of retinopathy of prematurity: results of the early treatment for retinopathy of prematurity randomized trial. Arch Ophthalmol, 2003, 121(12): 1684-1694. DOI: 10.1001/archopht.121.12.1684.
[2]	Cavallaro G, Filippi L, Bagnoli P, et al. The pathophysiology of retinopathy of prematurity: an update of previous and recent knowledge. Acta Ophthalmol, 2014, 92(1): 2-20. DOI: 10.1111/aos.12049.
[3]	M u e l l e r B , S a l c h o w D J , Wa ff e n s c h m i d t E , e t a l . Treatment of type I ROP with intravitreal bevacizumab or laser photocoagulation according to retinal zone. Br J Ophthalmol, 2017, 101(3): 365-370. DOI: 10.1136/ bjophthalmol-2016-308375.
[4]	Hwang CK, Hubbard GB, Hutchinson AK, et al. Outcomes after intravitreal bevacizumab versus laser photocoagulation for retinopathy of prematurity: a 5-year retrospective analysis. Ophthalmology, 2015, 122(5): 1008-1015. DOI: 10.1016/ j.ophtha.2014.12.017.
[5]	Hartnett ME. Role of cytokines and treatment algorithms in retinopathy of prematurity. Curr Opin Ophthalmol, 2017, 28(3): 282-288. DOI: 10.1097/ICU.0000000000000360.
[6]	VanderVeen DK, Melia M, Yang MB, et al. Anti-vascular endothelial growth factor therapy for primary treatment of type 1 retinopathy of prematurity: A report by the American academy of ophthalmology. Ophthalmology, 2017, 124(5): 619-633. DOI: 10.1016/j.ophtha.2016.12.025.
[7]	Avery RL, Bakri SJ, Blumenkranz MS, et al. Intravitreal injection technique and monitoring: updated guidelines of an expert panel. Retina, 2014, 34 Suppl 12: S1-S18. DOI: 10.1097/ IAE.0000000000000399.
[8]	Stahl A, Lepore D, Fielder A, et al. Ranibizumab versus laser therapy for the treatment of very low birthweight infants with retinopathy of prematurity (RAINBOW): an open-label randomised controlled trial. Lancet, 2019, 394(10208): 1551- 1559. DOI: 10.1016/S0140-6736(19)31344-3.
[9]	Kennedy KA, Mintz-Hittner HA. Medical and developmental outcomes of bevacizumab versus laser for retinopathy of prematurity. JAAPOS, 2018, 22(1): 61-65.e1. DOI: 10.1016/ j.jaapos.2017.10.006. Epub 2017 Dec 6.
[10]	Alyamaç Sukgen E, Çömez A, Koçluk Y, et al. The process of retinal vascularization after anti-VEGF treatment in retinopathy of prematurity: a comparison study between ranibizumab and bevacizumab. Ophthalmologica, 2016, 236(3): 139-147. DOI: 10.1159/000449530.
[11]	Roohipoor R, Karkhaneh R, Riazi-Esfahani M, et al. Comparison of intravitreal bevacizumab and laser photocoagulation in the treatment of retinopathy of prematurity.Ophthalmol Retina, 2018, 2(9): 942-948. DOI: 10.1016/j.oret.2018.01.017.
[12]	Wu WC, Shih CP, Lien R, et al. Serum vascular endothelial growth factor after bevacizumab or ranibizumab treatment for retinopathy of prematurity. Retina, 2017, 37(4): 694-701. DOI: 10.1097/IAE.0000000000001209.
[13]	Zhang J, Liang Y, Xie J, et al. Conbercept for patients with age-related macular degeneration: a systematic review. BMC ophthalmol, 2018, 18(1): 142. DOI: 10.1186/s12886-018-0807-1.
[14]	程湧, 梁建宏, 黎晓新. 康柏西普玻璃体腔注射治疗急进性后极部早产儿视网膜病变的疗效观察. 中华眼底病杂志, 2017, 33(2): 144-147. DOI: 10.3760/cma.j.issn.1005-1015.2017. 02.008.
[15]	张海涛, 万素华, 靳玮, 等. 康柏西普玻璃体腔注射治疗早产儿视网膜病变的疗效观察及其影响因素分析. 中华眼底病杂志, 2019, 35(2): 171-175. DOI: 10.3760/cma.j.issn.1005-1015. 2019.02.012.
[16]	Lu X, Sun X. Profile of conbercept in the treatment of neovascular age-related macular degeneration. Drug Des Devel Ther, 2015, 9: 2311-2320. DOI: 10.2147/DDDT.S67536.
[17]	Huang Q, Zhang Q, Fei P, et al. Ranibizumab injection as primary treatment in patients with retinopathy of prematurity: Anatomic outcomes and influencing factors. Ophthalmology, 2017, 124(8): 1156-1164. DOI: 10.1016/j.ophtha.2017.03.018.
[18]	Hu Q, Bai Y, Chen X, et al. Recurrence of retinopathy of prematurity in zone II stage 3+ after ranibizumab treatment: a retrospective study. J Ophthalmol, 2017, 2017: 5078565. DOI: 10.1155/2017/5078565.
[19]	Lorenz B, Stieger K, Jäger M, et al. Retinal vascular development with 0.312 mg intravitreal bevacizumab to treatsevere posterior retinopathy of prematurity: a longitudinal fluorescein angiographic study. Retina, 2017, 37(1): 97-111. DOI: 10.1097/IAE.0000000000001126.
[20]	Li Z, Zhang Y, Liao Y, et al. Comparison of efficacy between anti-vascular endothelial growth factor (VEGF) and laser treatment in Type-1 and threshold retinopathy of prematurity (ROP). BMC Ophthalmol, 2018, 18(1): 19. DOI: 10.1186/ s12886-018-0685-6.
[21]	Pertl L, Steinwender G, Mayer C, et al. A systematic review and meta-analysis on the safety of vascular endothelial growth factor (VEGF) inhibitors for the treatment of retinopathy of prematurity. PLoS One, 2015, 10(6): e0129383. DOI: 10.1371/ journal.pone.0129383.